Universal Platform, 24" 18 from Thermo Scientific
X-gal 10 g from Gold Biotechnology
dotMetric Protein Assay Sample Application Tips from Upstate
Rabbit/Goat RFC1 AbVantage Pack Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Biology Products:(Date:11/20/2009)...heir abstracts to the World Congress on Osteoporos...ting devoted to all aspects of osteoporosis and os...ss will be held in Florence, Italy from May 5-8, 2...ed online at http://www.iofwco-ecceo10.org , ...OF and ESCEO are pleased to announce that seven sp...
(Date:11/20/2009)...ogical molecules like RNA and DNA is how they firs...precursors. Now, in a study appearing in this week...e of the earliest evolutionary steps yet: generati...ng nothing but warm water. , Many researchers b...lecules present, before DNA and proteins; however,...
(Date:11/20/2009)...ased sealcoats in parking lots may be the culprit ...udy. PAHs or polycyclic aromatic hydrocarbons a...sits, and can have toxic effects. It,s long been k...ver, the specific sources of these PAHs are largel...ndoor areas near parking lots with coal-tar-based ...
Breaking Biology News(10 mins):Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3From toxic dust and algae to ill winds from Africa 2From toxic dust and algae to ill winds from Africa 3From toxic dust and algae to ill winds from Africa 4From toxic dust and algae to ill winds from Africa 5Pennsylvania Department of Health Workshops Will Help Businesses Prepare for Flu Pandemic 50436 1Pennsylvania Department of Health Workshops Will Help Businesses Prepare for Flu Pandemic 50436 2Creighton University St Josephs Hospital and Medical Center Announce New School of Medicine Campus in Phoenix 50434 1Creighton University St Josephs Hospital and Medical Center Announce New School of Medicine Campus in Phoenix 50434 2Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 1Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 2Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 3Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 4Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 5(Date:11/19/2009)...L, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc....n a randomized Phase 2B study of AEG35156, a targe... for multiple oncology indications. ,, The stud...y of the X-Linked Inhibitor of Apoptosis (XIAP) An...se Cytarabine and Idarubicin in AML Following Fail...
(Date:11/18/2009)...alif., Nov. 18 Marrone Bio Innovat... and commercialization of effective and environmen...ced that it has been named an IC20 company by the ...argest national angel investing group. ,, Compa...g to rewarding results for all stakeholders, inclu...
(Date:11/18/2009)...ND, Calif., Nov. 18 Sang...oday that data from the University of Pennsylvania...ngamo,s zinc finger nuclease (ZFN) based product, ...aturely disclosed on the internet. ,, Data were...f Pennsylvania School of Medicine from a single su...
(Date:11/18/2009)...UGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioSc...iences product development company that identifies...cer-related products at various stages of developm...g nimotuzumab were presented today in a poster at ...er Therapeutics conference in Boston, Massachusett...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Marrone Bio Innovations Named an IC20 Company 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3